| 代码 | 简称 | 收盘价（元） | 涨跌幅（%） | 换手率（%） | 成交额（万元） | | --- | --- | --- | --- | --- | --- | | 832982 | 锦波生物 | 446.50 | -3.56 | 3.74 | 77095.81 | | 920799 | 艾融软件 | 60.71 | 7.85 | 9.72 | 68407.56 | | 833171 | 国航远洋 | 10.51 | 3.85 | 18.64 | 55840.33 | | 873806 | 云星宇 | 17.94 | 16.49 | 10.40 | 53476.95 | | 835579 | 机科股份 | 35.05 | 14.06 | 32.00 | 48119.37 | | 831370 | 新安洁 | 6.14 | 16.95 | 28.93 | 46477.81 | | 920128 | 胜业电气 | 44.88 | 13.56 | 48.87 | 44850.95 | | 871396 | 常辅股份 | 47.70 | -0.93 | 21.93 | 44419.11 | | 83378 ...

Core Viewpoint - Taiyuan City is focusing on industrial transformation and the cultivation of strategic emerging industries, enhancing innovation and establishing a green manufacturing system to drive high-quality economic development [1][31]. Group 1: Macroeconomic Analysis - Taiyuan's GDP for 2024 is projected to be CNY 541.887 billion, with a growth rate of 1.2%. The primary, secondary, and tertiary industries contribute CNY 4.785 billion, CNY 166.671 billion, and CNY 370.431 billion respectively, with the tertiary sector growing by 1.6% [2][4]. - The proportion of strategic emerging industries in Taiyuan's industrial output is increasing, with a 2024 forecast showing a 37.3% contribution to the total industrial output, up 1.4 percentage points from the previous year [4]. Group 2: Investment Trends - Fixed asset investment in Taiyuan is expected to grow by 0.5% in 2024, with 136 ongoing projects valued over CNY 1 billion, representing 35.9% of total investment [6]. - Industrial investment is projected to account for 27.7% of total investment, with a significant increase of 24.7% year-on-year [6]. Group 3: Industrial Structure - Taiyuan is constructing a modern industrial system centered around the "1233" key industrial chain system, which includes nine major industrial chains contributing approximately 70% of the city's industrial output [10][31]. - The "1233" system focuses on high-end metal materials, advanced carbon-based materials, and advanced biological materials, among others, with 118 key enterprises involved [10][31]. Group 4: Innovation and R&D - In 2023, Taiyuan's R&D expenditure reached CNY 12.79 billion, ranking first in Shanxi Province, indicating a strong focus on innovation [8]. - The city is implementing four major projects to enhance innovation capabilities, including optimizing the innovation ecosystem and promoting the transformation of innovative results [8]. Group 5: Key Industries - The high-end metal materials industry is a pillar of Taiyuan's economy, with significant products including special steel and new magnesium alloys, generating CNY 118.3 billion in revenue in 2023 [19][20]. - The carbon-based materials industry is leveraging local coal resources and advanced research capabilities, with a focus on both traditional and cutting-edge carbon materials [25][27]. - The advanced biological materials and biopharmaceutical industry is developing rapidly, focusing on bio-based new materials and recombinant human collagen protein [29]. Group 6: Policy Framework - Taiyuan has introduced several policies to support high-quality development, including plans for digital transformation and the establishment of advanced manufacturing bases [16][18]. - The city aims to achieve significant results in industrial high-quality development by 2025, enhancing its competitive advantages [16].

山西锦波生物医药股份有限公司 章 程 二〇二五年五月 山西锦波生物医药股份有限公司章程 山西锦波生物医药股份有限公司章程 第一章 总则 第一条 为维护山西锦波生物医药股份有限公司（以下简称"公司"或"本 公司"）、股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民 共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简 称《证券法》）、《北京证券交易所股票上市规则（试行）》（以下简称《上市 规则》）和其他有关法律法规、行政规章、规范性文件的规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。 公司由太原锦波生物医药科技有限公司依法整体变更设立。在山西省太原市 工商行政管理局注册登记，取得营业执照，统一社会信用代码为： 91140100672338346F。 第三条 公司全部资产分为等额股份，股东以其认购的股份为限对公司承担 责任，公司以其全部资产对公司的债务承担责任。 第四条 本章程自生效之日起，即成为规范公司的组织与行为、公司与股东、 股东与股东之间权利义务关系的具有法律约束力的文件，对公司、股东、董事、 监事、高级管理人员具有法律约束力的法律文件。依 ...

证券代码：832982 证券简称：锦波生物 公告编号：2025-064 山西锦波生物医药股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 5 月 21 日 2.会议召开地点：山西综改示范区太原唐槐园区锦波街 18 号公司九楼会议 室 3.会议召开方式：现场投票及网络投票 4.会议召集人：公司董事会 5.会议主持人：董事长杨霞女士 6.召开情况合法合规的说明： 本次股东会的召集、召开程序符合有关法律、行政法规、部门规章、规范性 文件和本公司章程的相关规定。本次会议召开不需要相关部门的批准或履行其他 必要的程序。 （二）会议出席情况 同意股数 53,902,177 股，占本次股东会有表决权股份总数的 100%；反对股 数 0 股，占本次股东会有表决权股份总数的 100%；弃权股数 0 股，占本次股东 会有表决权股份总数的 100%。 2.回避表决情况 出席和授权出席本次股东会的股东共 33 ...

G E Y U A N 格 远 律 师 事 务 所 Law Firm 关于山西锦波生物医药股份有限公司 2024 年年度股东会的 法律意见书 山西格远律师事务所 )二五年五 山西格远律师事务所 关于山西锦波生物医药股份有限公司 2024 年年度股东会的 法律意见书 致:山西锦波生物医药股份有限公司 根据《中华人民共和国证券法(2019年修订)》(以下简称"《证券法》")《中 华人民共和国公司法(2023年修正)》(以下简称"《公司法》")《北京证券交易 所上市公司持续监管办法》《上市公司信息披露管理办法》等法律、法规和其他 有关规范性文件的要求,山西格远律师事务所(以下简称"本所")接受山西锦 波生物医药股份有限公司(以下简称"锦波生物"或"公司")的委托,指派律 师参加公司 2024年年度股东会(以下简称"本次股东会"或"本次会议")。 均真实有效:所有相关自然人均具有完全民事行为能力;锦波生物相关工作人员 口头介绍的情况均是真实、准确、完整的。本所律师依法对出具本《法律意见书》 所依据的文件资料的真实性、准确性、完整性进行了核查和验证。核查和验证时, 本所律师对与法律相关的事项履行法律专业人士特别的注意义 ...

Market Overview - On May 23, the total trading volume of stocks on the Beijing Stock Exchange reached 1.269 billion shares, with a total transaction value of 27.181 billion yuan, a decrease of 10.005 billion yuan compared to the previous trading day [1] - Among the tradable stocks, 57 stocks closed higher, accounting for 21.43% of the total, with notable gainers including Chenguang Medical, Changfu Co., and Senxuan Pharmaceutical, which rose by 14.96%, 10.12%, and 9.73% respectively [1] - Conversely, 208 stocks closed lower, with the largest declines seen in Kexin New Materials, Shengnan Technology, and Air China Ocean, which fell by 9.04%, 8.54%, and 7.89% respectively [1] Trading Activity - A total of 87 stocks had transaction values exceeding 10 million yuan, with the highest transaction values recorded for Jinbo Biological, Changfu Co., and Wuxin Tunnel Equipment, at 813 million yuan, 597 million yuan, and 517 million yuan respectively [1] - In terms of trading activity, 48 stocks had a turnover rate exceeding 10%, with 8 stocks exceeding 20%. Additionally, 94 stocks had turnover rates between 5% and 10%, while 122 stocks had turnover rates between 1% and 5% [1] - The stocks with the highest turnover rates included Ningxin New Materials, Chenguang Medical, and Changfu Co., with turnover rates of 33.42%, 32.11%, and 31.21% respectively [1] Stock Performance - The closing prices and performance of notable stocks included: - Jinbo Biological: Closing price of 497.70 yuan, up 0.85%, turnover rate of 3.54%, transaction value of 812.56 million yuan [1] - Changfu Co.: Closing price of 45.90 yuan, up 10.12%, turnover rate of 31.21%, transaction value of 597.47 million yuan [1] - Wuxin Tunnel Equipment: Closing price of 41.27 yuan, down 7.28%, turnover rate of 14.02%, transaction value of 516.61 million yuan [1] - Chenguang Medical: Closing price of 21.90 yuan, up 14.96%, turnover rate of 32.11%, transaction value of 473.16 million yuan [1] - Air China Ocean: Closing price of 10.04 yuan, down 7.89%, turnover rate of 15.90%, transaction value of 473.14 million yuan [1]

作 者丨彭卓 尹华禄 编 辑丨梁明 陈思颖 5月2 2日，市场全天震荡调整，创业板指领跌，北证5 0指数跌超6%。南财金融终端显示，截 至收盘，沪指跌0 . 2 2%，深成指跌0 . 7 2%，创业板指跌0 . 9 6%。 | 行情 | 资金净流入 | 涨跌分布 | | --- | --- | --- | | 上证指数 | 深证成指 | 北证50 | | 3380.19 | 10219.62 | 1388.83 | | -7.39 -0.22% - - 74.60 - - 0.72% - - 90.98 - - 6.15% | | | | 科创50 | 创业板指 | 万得全A | | 990.71 | 2045.57 | 5122.66 | | -4.78 -0.48% - | | -19.82 -0.96% -32.48 -0.63% | | 沪深300 | 中证500 | 中证A500 | | 3913.87 | 5703.28 | 4585.83 | | -2.52 - - 0.06% - - 54.64 - - 0.95% - - 13.83 - - 0.30% | | | | 中证1000 | 深证 ...

Market Performance - The micro-cap stock index opened lower but surged over 1% to reach a historical high before closing down 1.37% [2] - The North Exchange 50 index experienced a significant decline, closing down 6.15% after reaching a historical high the previous day [2] Reasons for Adjustment - Analysts suggest that the recent market adjustment is due to both internal and external factors, including a historical pattern where high levels of congestion in the market led to significant pullbacks [3] - The micro-cap sector may face profit-taking pressure as funds become overly concentrated, potentially shifting market preference towards mid and large-cap stocks [3] Company-Specific Insights - Jinbo Biological (832982.BJ) saw its stock price drop over 17% during the day, closing down 14.55%. The company attributed the decline to market factors rather than specific company issues [3] - Jinbo Biological's stock had been on a steady rise since March, reaching a peak of 589.98 CNY per share on May 22, with a total market capitalization exceeding 52 billion CNY [3] - The company is recognized for its innovative medical device, the "recombinant type III humanized collagen freeze-dried fiber," which is the first of its kind in China, laying a solid foundation for clinical applications and industrial transformation [4] Market Sentiment - The poor results from the U.S. 20-year Treasury auction have led to a negative sentiment in the U.S. financial markets, potentially increasing global risk aversion and cautiousness [5] - There are indications that micro-cap stock investments may be overly crowded, with trading volumes surpassing previous highs, signaling significant overbought conditions [5]

证券时报·数据宝统计，截至下午13:58，今日沪指跌0.06%，A股成交量769.43亿股，成交金额9059.95亿 元，比上一个交易日减少7.18%。个股方面，1184只个股上涨，其中涨停45只，4124只个股下跌，其中 跌停15只。从申万行业来看，银行、国防军工、传媒等涨幅最大，涨幅分别为0.64%、0.40%、0.24%； 美容护理、基础化工、社会服务等跌幅最大，跌幅分别为3.43%、1.37%、1.35%。（数据宝） 今日各行业表现（截至下午13:58） （文章来源：证券时报网） | 房地产 | | | | 三湘印象 | | | --- | --- | --- | --- | --- | --- | | 社会服务 | -1.35 | 73.33 | 3.98 | 国义招标 | -5.94 | | 基础化工 | -1.37 | 558.32 | -15.99 | 宁新新材 | -15.04 | | 美容护理 | -3.43 | 111.40 | 12.49 | 锦波生物 | -14.98 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 | 申万行业 | 行业涨跌（%） | 成交额（亿元 ...

Group 1 - The Beijng Stock Exchange 50 Index fell over 6% in the afternoon session [1] - Jinbo Biological, a constituent stock, led the decline with a drop of over 16% [1]